Skip to main content

Peer Review reports

From: Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

Original Submission
27 Jun 2018 Submitted Original manuscript
9 Aug 2018 Author responded Author comments - William McGuire
Resubmission - Version 2
9 Aug 2018 Submitted Manuscript version 2
1 Sep 2018 Reviewed Reviewer Report - Claire F. Verschraegen
15 Sep 2018 Reviewed Reviewer Report - Franco M. Muggia
21 Sep 2018 Reviewed Reviewer Report - Robert Naumann
30 Oct 2018 Author responded Author comments - William McGuire
Resubmission - Version 3
30 Oct 2018 Submitted Manuscript version 3
2 Nov 2018 Reviewed Reviewer Report - Claire F. Verschraegen
21 Nov 2018 Reviewed Reviewer Report - Franco M. Muggia
6 Dec 2018 Author responded Author comments - William McGuire
Resubmission - Version 4
6 Dec 2018 Submitted Manuscript version 4
Publishing
9 Dec 2018 Editorially accepted
27 Dec 2018 Article published 10.1186/s12885-018-5198-4

You can find further information about peer review here.

Back to article page